KBC Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

KBC Group’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-22,692	Closed	-$238K	–	1300
2017 Q2	$238K	Buy	+22,692	New	+$231K	﹤0.01%	1096

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KBC Group's SCMP Position: Q3 2017 in Review

KBC Group sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2017, closing a stake of 22,692 shares — an estimated $238K sold.

KBC Group first reported a position in SCMP in Q2 2017 and held it in 1 quarter. The position peaked at $238K in Q2 2017. 178 funds tracked by Wall St. Rank hold SCMP as of Q3 2017.

KBC Group reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
KBC Group sold 22,692 Sucampo Pharmaceuticals, Inc. shares in Q3 2017, an estimated $238K.
KBC Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
KBC Group's Sucampo Pharmaceuticals, Inc. position peaked at $238K in Q2 2017.
178 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2017.

Based on KBC Group's 13F filing for Q3 2017, filed 13 Nov 2017.